Clariane extends debt maturities with €500m bond and new €700m credit facility

Clariane has launched a proposed €500 million senior bond offering as the European healthcare and long-term care group continues a sweeping refinancing program aimed at simplifying its capital structure, extending maturities and preserving liquidity. The euro-denominated notes will mature in 2032, with proceeds and available cash earmarked to repay a €350 million term loan and a separate €150 million real estate term loan. Clariane has also secured bank support, conditional on completion of the bond offering, for a new €700 million five-year revolving credit facility that would replace its existing syndicated facility and could expand to as much as €900 million. If the new bond is completed, Clariane will have launched approximately €1.56 billion of senior and hybrid bond financing during 2026, although much of that capital is refinancing existing obligations rather than reducing debt outright.

The September 7 announcement arrives after Clariane reported improving operating performance and a meaningful year-over-year reduction in net financial debt during the first half. Revenue reached €2.70 billion, organic growth was 4.6% and pre-IFRS 16 EBITDA rose 14.9% on a pro forma basis excluding disposals to €280 million. Net financial debt excluding IFRS 16 and IAS 17 stood at €3.02 billion at June 30, down €539 million from a year earlier, while the company continues targeting Wholeco leverage below 5.5 times by the end of 2026.

Clariane’s €500 million bond replaces existing loans rather than simply adding new leverage

The proposed financing is structured principally as a liability-management transaction. Clariane intends to use the net proceeds, together with cash already on its balance sheet, to repay and cancel a €350 million term loan under its existing facilities agreement and a €150 million real estate term loan, while also covering fees and expenses associated with the new offering.

That distinction matters for investors because issuing €500 million of new notes does not mean Clariane is simply adding another €500 million to its existing debt burden. The company is replacing bank and real estate term loans with longer-dated capital-market debt, potentially reducing refinancing concentration and moving a meaningful portion of its obligations out to 2032.

The final economics remain incomplete because Clariane had not disclosed the coupon or issue price of the new notes when the offering was launched. Completion also remains subject to market conditions, meaning the cost of refinancing will be important in determining whether the transaction improves not only maturity visibility but also future interest expense.

S&P Global Ratings assigned the proposed €500 million senior notes a B+ rating and a recovery rating of 3, indicating its expectation of meaningful recovery in a hypothetical default scenario. Clariane itself received inaugural corporate ratings of B+ from S&P Global Ratings and B2 from Moody’s Ratings earlier in 2026 as the company worked to normalize access to bond markets following its balance-sheet restructuring.

The bond also fits into a much larger financing program. In April, Clariane issued €500 million of 6.875% senior notes due in 2031 and subsequently added another €230 million of the same securities. In June, it issued €333 million of deeply subordinated hybrid notes carrying an initial 7.875% coupon, taking first-half bond and hybrid issuance to €1.063 billion before the latest proposed €500 million transaction.

If the September offering completes at its proposed size, cumulative 2026 issuance across those transactions would therefore reach approximately €1.563 billion. That figure illustrates the scale of Clariane’s refinancing effort, but the more important question is what the transactions replace because much of the proceeds are being used to retire earlier financing instruments rather than fund acquisitions or operating expansion.

New €700 million revolving facility could improve liquidity flexibility while tightening leverage discipline

Clariane has also obtained agreement from its banking partners to replace its existing syndicated credit facility with a new €700 million revolving credit facility, subject to completion of the bond offering. The facility would have a five-year maturity and an accordion feature allowing its size to increase to as much as €900 million, potentially giving the company a substantial liquidity buffer for capital expenditure, general corporate requirements and future debt refinancing.

Drawn amounts would carry a variable interest rate equal to EURIBOR plus a margin ranging from 1.75% to 3.50%, depending on Clariane’s Wholeco total net leverage ratio. The pricing would also include an environmental, social and governance-linked adjustment mechanism, directly connecting a portion of borrowing costs to both balance-sheet leverage and sustainability metrics.

The new facility would use Wholeco leverage as its single financial covenant. The maximum threshold would remain below 7.0 times through June 2027 before declining progressively to 6.75 times in December 2027, 6.50 times in June 2028, 6.25 times in December 2028 and 6.0 times from June 2029 onward.

Those thresholds provide Clariane with meaningful near-term headroom compared with its current leverage position, but they also establish a clear pathway toward tighter financial discipline over time. Wholeco leverage stood at 4.9 times on a reported basis at June 30 and would have been approximately 5.4 times after adjusting for the June hybrid proceeds earmarked for redemption of the company’s ODIRNANE securities.

The revolving facility would also restrict distributions under certain conditions. Annual dividend distributions would be limited to 7% of Clariane’s market capitalization and would require Wholeco leverage not to exceed 4.5 times, meaning meaningful shareholder distributions remain tied to further balance-sheet improvement.

For investors, that structure reinforces the priority management is placing on financial resilience rather than aggressively returning capital while leverage remains elevated. The facility potentially improves access to liquidity, but its pricing and distribution restrictions continue to reward faster deleveraging.

Improving healthcare operations give Clariane more capacity to support its refinancing strategy

The balance-sheet restructuring is occurring alongside a measurable improvement in underlying operations. First-half revenue rose 4.6% organically to €2.70 billion, while pre-IFRS 16 EBITDA increased to €280 million from €263 million on a reported basis and rose 14.9% compared with the prior-year pro forma figure excluding disposals. The EBITDA margin improved to 10.4% from 9.5% on the comparable pro forma basis.

Opco EBITDA, which Clariane uses to reflect operating profitability after adjusting for its real estate structure, increased 25.1% on a pro forma basis to €168 million. The corresponding margin improved to 6.2% from 5.2%, supported by higher occupancy, pricing actions, cost controls and stronger performance particularly in Germany and specialty care operations in France.

Long-term care remains the core business, accounting for approximately 75% of group revenue. Revenue from that segment reached €2.02 billion in the first half and increased 5% organically, while average occupancy in medicalized nursing homes improved to 91.7% from 90.5% a year earlier. Specialty care contributed another €676 million of revenue and grew 3.2% organically.

Cash generation is improving more gradually. Operating cash flow increased to €144 million from €133 million, although free operating cash flow declined slightly to €20 million after higher interest and tax payments. Net free cash flow improved substantially to a €4 million outflow from a €48 million outflow a year earlier, demonstrating progress even though the company has not yet reached consistently strong free cash generation.

Reported profitability also remains a work in progress. Clariane recorded a €48 million net loss attributable to shareholders after IFRS 16 during the first half, compared with a €59 million loss a year earlier, while financial expenses continued to absorb a substantial portion of operating earnings. That makes the cost and maturity structure of future financing particularly relevant because operating improvements can translate more effectively into shareholder earnings if interest burdens become more manageable.

Clariane shares show limited reaction as investors focus on leverage and future refinancing costs

Clariane shares closed September 7 at approximately €3.95 on Euronext Paris, down about 0.75% for the session, suggesting investors viewed the proposed bond primarily as another stage in an already established refinancing strategy rather than a major change to the equity story. The stock remains inside a 52-week range of roughly €3.27 to €4.89, while its market capitalization is around €1.4 billion.

The relatively muted share-price response is understandable because today’s announcement does not reduce leverage immediately. Clariane is principally exchanging one form of borrowing for another while adding a larger revolving liquidity facility, so the long-term benefit depends on maturity extension, interest expense, operating cash generation and continued debt reduction rather than the headline size of the transaction alone.

There has nevertheless been significant progress compared with a year earlier. Net financial debt excluding IFRS 16 and IAS 17 declined by €539 million year over year to €3.02 billion at June 30, and Clariane continues to target net debt around €3 billion and Wholeco leverage below 5.5 times by the end of 2026.

The earlier 2026 refinancing transactions also demonstrate why changing the composition of debt can matter. Clariane used the €230 million April bond addition to retire £200 million of perpetual green hybrid securities that were carrying a 13.168% coupon, replacing particularly expensive financing with 6.875% senior debt. Management estimated that the refinancing transactions completed during the first half would improve annual cash generation by approximately €27 million once the associated repayments were completed.

The September bond could extend that process, but investors should watch the final coupon carefully. European financing conditions remain sensitive to interest rates and credit spreads, and Clariane’s sub-investment-grade rating means the company pays a meaningful premium relative to highly rated issuers.

The broader investment case therefore rests on two developments progressing together. Operating improvement needs to increase EBITDA and cash flow while liability management reduces refinancing risk and gradually lowers leverage, creating a stronger balance sheet without sacrificing investment in long-term care and specialty healthcare operations.

Clariane has made substantial progress in regaining capital-market access and reshaping maturities during 2026. The proposed €500 million bond and €700 million revolving facility could provide another step toward a more stable financing structure, but sustainable value creation will depend on continued deleveraging rather than repeated refinancing alone.

Key takeaways from Clariane’s €500 million bond offering and wider debt refinancing strategy

• Clariane launched €500 million of new senior notes due in 2032 to refinance a €350 million term loan and €150 million real estate term loan.
• If completed, the transaction would take Clariane’s total senior and hybrid bond issuance announced during 2026 to approximately €1.56 billion.
• The financing primarily replaces existing obligations rather than creating an equivalent increase in net debt, with maturity extension and liquidity flexibility forming the main strategic benefits.
• Clariane has also secured conditional bank backing for a new €700 million five-year revolving facility that could expand to as much as €900 million.
• The revolving facility would price at EURIBOR plus 1.75% to 3.50%, depending largely on Clariane’s Wholeco leverage ratio.
• Net financial debt excluding IFRS 16 and IAS 17 fell €539 million year over year to approximately €3.02 billion at June 30.
• First-half revenue reached €2.70 billion, while pre-IFRS 16 EBITDA rose 14.9% on a pro forma basis to €280 million and its margin improved to 10.4%.
• Wholeco leverage stood at 4.9 times on a reported basis and approximately 5.4 times after adjusting for the planned ODIRNANE refinancing.
• Clariane shares closed September 7 around €3.95, down modestly as investors weighed improved refinancing visibility against still-elevated leverage.
• The final coupon on the new bonds, continued operating cash-flow improvement and progress toward year-end leverage below 5.5 times will be critical indicators for investors.